Abstract
Classically, mast cells (MC) are considered as important actors of the innate immune response playing a pivotal role in IgE-mediated allergic and antiparasite responses. In the last two decades, many experimental evidences demonstrated that these hematopoietic-derived cells present in both connective and mucosal tissues are also key modulators of the adaptive immune response and could contribute to autoimmune disease notably in rheumatoid arthritis (RA). Recently, Bader-Meunier et al. reported a series of 31 patients suffering from inflammatory joint diseases associated with mastocytosis, suggesting that mastocytosis was associated with a higher prevalence in spondyloarthritis. We discuss here the possible link between chronic inflammatory arthritis and mastocytosis through the report of a clinical case describing a patient developing RA after a long history of mastocytosis. Of great interest, antihistamine treatment alone was sufficient to treat RA in this patient.
Similar content being viewed by others
References
Aletaha D, Neogi T, Silman AJ, et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588. doi:10.1136/ard.2010.138461
Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373:163–172. doi:10.1056/NEJMra1409760
Cruse G, Metcalfe DD, Olivera A (2014) Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin N Am 34:219–237. doi:10.1016/j.iac.2014.01.002
Magliacane D, Parente R, Triggiani M (2014) Current concepts on diagnosis and treatment of mastocytosis. Transl Med UniSa 8:65–74
Golkar L, Bernhard JD (1997) Mastocytosis. Lancet 349:1379–1385. doi:10.1016/S0140-6736(96)07056-0
DeBruin EJ, Gold M, Lo BC, et al. (2015) Mast cells in human health and disease. Methods Mol Biol 1220:93–119. doi:10.1007/978-1-4939-1568-2_7
Moon TC, St Laurent CD, Morris KE, et al. (2010) Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 3:111–128. doi:10.1038/mi.2009.136
Gurish MF, Boyce JA (2006) Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 117:1285–1291. doi:10.1016/j.jaci.2006.04.017
Kalesnikoff J, Galli SJ (2008) New developments in mast cell biology. Nat Immunol 9:1215–1223. doi:10.1038/ni.f.216
Urb M, Sheppard DC (2012) The role of mast cells in the defence against pathogens. PLoS Pathog 8:e1002619. doi:10.1371/journal.ppat.1002619
Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440–452. doi:10.1038/nri2782
Galli SJ, Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18:693–704. doi:10.1038/nm.2755
Cruse G, Bradding P (2015) Mast cells in airway diseases and interstitial lung disease. Eur J Pharmacol. doi:10.1016/j.ejphar.2015.04.046
Barete S, Assous N, de Gennes C, et al. (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841. doi:10.1136/ard.2009.124511
Biosse-Duplan M, Baroukh B, Dy M, et al. (2009) Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 174:1426–1434. doi:10.2353/ajpath.2009.080871
Rossini M, Zanotti R, Viapiana O, et al. (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127:1127.e1–1127.e4. doi:10.1016/j.amjmed.2014.06.015
Guillaume N, Desoutter J, Chandesris O, et al. (2013) Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 126:75.e1–75.e7. doi:10.1016/j.amjmed.2012.07.018
Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 124:776–778. doi:10.1016/j.amjmed.2011.02.038
Marshall A, Kavanagh RT, Crisp AJ (1997) The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36:393–396
Brumsen C, Hamdy NAT, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569. doi:10.1359/jbmr.2002.17.4.567
Lim AYN, Ostor AJK, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966. doi:10.1136/ard.2004.029116
Kay J, Upchurch KS (2012) ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(Suppl 6):vi5–vi9. doi:10.1093/rheumatology/kes279
Gotis-Graham I, McNeil HP (1997) Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum 40:479–489
McNeil HP, Gotis-Graham I (2000) Human mast cell subsets--distinct functions in inflammation? Inflamm Res 49:3–7
Olsson N, Ulfgren AK, Nilsson G (2001) Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann Rheum Dis 60:187–193. doi:10.1136/ard.60.3.187
Buckley MG, Walters C, Wong WM, et al. (1997) Mast cell activation in arthritis: detection of alpha- and beta-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci 93:363–370
Hueber AJ, Asquith DL, Miller AM, et al. (2010) Mast cells express IL-17 A in rheumatoid arthritis synovium. J Immunol 184:3336–3340. doi:10.4049/jimmunol.0903566
Noordenbos T, Yeremenko N, Gofita I, et al. (2012) Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 64:99–109. doi:10.1002/art.33396
Moulin D, Donzé O, Talabot-Ayer D, et al. (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40:216–225. doi:10.1016/j.cyto.2007.09.013
Suurmond J, Rivellese F, Dorjée AL, et al. (2014) Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-205562
Suurmond J, van Heemst J, van Heiningen J, et al. (2013) Communication between human mast cells and CD4(+) T cells through antigen-dependent interactions. Eur J Immunol 43:1758–1768. doi:10.1002/eji.201243058
Nakae S, Suto H, Kakurai M, et al. (2005) Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 102:6467–6472. doi:10.1073/pnas.0501912102
Baram D, Vaday GG, Salamon P, et al. (2001) Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol 167:4008–4016
Suurmond J, van der Velden D, Kuiper J, et al. (2015) Mast cells in rheumatic disease. Eur J Pharmacol. doi:10.1016/j.ejphar.2015.03.085
Magarinos NJ, Bryant KJ, Fosang AJ, et al. (2013) Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and −13 zymogens. J Immunol 191:1404–1412. doi:10.4049/jimmunol.1300856
Seitz S, Barvencik F, Koehne T, et al. (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24:2325–2334. doi:10.1007/s00198-013-2305-x
Bader-Meunier B, Livideanu CB, Larroche C, et al. (2014) Association of mastocytosis with inflammatory joint diseases_ a series of 31 patients. Semin Arthritis Rheum 44:362–365. doi:10.1016/j.semarthrit.2014.05.016
Eklund KK (2007) Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 217:38–52. doi:10.1111/j.1600-065X.2007.00504.x
Acknowledgments
Study design was performed by ICV and DM; study conduct, IL and MK; data collection, ICV and DL; drafting the manuscript, IL, MK, JH, and DM; revising the manuscript content, MK, DL, PN, JYJ, ICV, and DM; approving the final version of the manuscript, IL, MK, JH, DL, PN, JYJ, ICV, and DM; DM and ICV takes responsibility for the integrity of the data analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Ichraq Latar and Meriem Koufany contributed equally to this work. Isabelle Chary-Valckenaere and David Moulin contributed equally to this work.
Electronic supplementary material
ESM. 1
(PPTX 434 kb)
Rights and permissions
About this article
Cite this article
Latar, I., Koufany, M., Hablot, J. et al. Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review. Clin Rheumatol 35, 2619–2623 (2016). https://doi.org/10.1007/s10067-016-3368-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-016-3368-9